Manhattan Scientifics (Manhattan Scientifics) Change In Working Capital : $0.55 Mil (TTM As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Manhattan Scientifics Change In Working Capital?

Manhattan Scientifics's change in working capital for the quarter that ended in Mar. 2024 was $0.15 Mil.

Manhattan Scientifics's change in working capital for the fiscal year that ended in Dec. 2023 was $0.51 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Manhattan Scientifics Change In Working Capital Historical Data

The historical data trend for Manhattan Scientifics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Manhattan Scientifics Change In Working Capital Chart

Manhattan Scientifics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.34

0.26

0.17

0.33

0.51

Manhattan Scientifics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															0.11	0.12	0.14	0.14	0.15

Manhattan Scientifics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Manhattan Scientifics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Manhattan Scientifics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Manhattan Scientifics (Manhattan Scientifics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Manhattan Scientifics Inc (OTCPK:MHTX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001

Website

http://www.mhtx.com

Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The company is focused on technology transfer and commercialization of transformative technologies.

Executives

Chris Theoharis	director	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Photios Frank Georgiou	director	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Emmanuel Tsoupanarias	director, officer: Chief Executive Officer	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Leonard Friedman	director	405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Marvin Maslow	director, 10 percent owner, officer: Chief Executive Office	MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
David Teich	director, officer: Treasurer	MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
Ralph Anderson	director	641 FIFTH AVENUE SUITE 36F, NEW YORK NY 10022
Larry H Schatz	director	152 W. 57TH STREET, 31ST FLOOR, NEW YORK NY 10019
Marty Steinberg	10 percent owner	1111 BRICKELL AVENUE SUITE 2500, MIAMI FL 33131
Scott Bach	director, officer: Secretary	MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022

Manhattan Scientifics (Manhattan Scientifics) Headlines

No Headlines